Anti‐PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

“…Recommended dose depends on the treated neoplasm and its dose for cSCC is 3 mg/ kg of weight every 2 weeks administered as iv infusion over 30 minutes. About the efficacy of this drug, the number of reported cases is only 12 (Blum et al, 2018;Borradori et al, 2016;Miller et al, 2017;Pickering et al, 2014;Schwab et al, 2016;Sellah et al, 2019;Tran et al, 2017), with a short duration follow-up, the longest about 12 months (Blum et al, 2018). Blum et al (2018) Generalized muscle weakness, fatigue, acute autoimmune hemolysis 5 months and stop for acute hemolysis proposed by Sellah et al (2019), which showed three cases of Stage III, one of them with eight cycles and 10 months of follow-up free of disease recurrence with only anemia reported among adverse events (LE 4 following Oxford CEBM Levels of Evidence).…”

“…Good response was demonstrated by Chen et al () and Pickering et al () with one patient in Stage IV who has undergone a combine therapy with Nivolumab and Cetuximab, an antibody against EGFR, and after 12 months of treatment the patient remained free of disease (LE 4 following Oxford CEBM Levels of Evidence). Another example of combination therapy was reported by Miller et al () and Sellah et al () with the association of Nivolumab with Ipilimumab, an anti‐CTLA‐4 antibody (LE 4 following Oxford CEBM Levels of Evidence). The patient affected by diabetes and undergone renal transplantation, highlighted acute allograft rejection and subsequently death for cardiac injury not associated to the treatment but for his long history of diabetes (Sellah et al, ).…”

“…Another example of combination therapy was reported by Miller et al () and Sellah et al () with the association of Nivolumab with Ipilimumab, an anti‐CTLA‐4 antibody (LE 4 following Oxford CEBM Levels of Evidence). The patient affected by diabetes and undergone renal transplantation, highlighted acute allograft rejection and subsequently death for cardiac injury not associated to the treatment but for his long history of diabetes (Sellah et al, ). Regarding the adverse events, it seems to be the same of the others PD‐1 inhibitors, fatigue, anemia, autoimmune thyroiditis and no associated therapy deaths are revealed.…”

“…Recommended dose depends on the treated neoplasm and its dose for cSCC is 3 mg/kg of weight every 2 weeks administered as iv infusion over 30 minutes. About the efficacy of this drug, the number of reported cases is only 12 (Blum et al, ; Borradori et al, ; Miller et al, ; Pickering et al, ; Schwab et al, ; Sellah et al, ; Tran et al, ), with a short duration follow‐up, the longest about 12 months (Blum et al, ). Blum et al () proposed three cases of Stage IV patients treated for over 12 months demonstrating partial response without particular adverse events (LE 4 following Oxford CEBM Levels of Evidence).…”

“…Blum et al () proposed three cases of Stage IV patients treated for over 12 months demonstrating partial response without particular adverse events (LE 4 following Oxford CEBM Levels of Evidence). Reports with complete response were proposed by Sellah et al (), which showed three cases of Stage III, one of them with eight cycles and 10 months of follow‐up free of disease recurrence with only anemia reported among adverse events (LE 4 following Oxford CEBM Levels of Evidence). Good response was demonstrated by Chen et al () and Pickering et al () with one patient in Stage IV who has undergone a combine therapy with Nivolumab and Cetuximab, an antibody against EGFR, and after 12 months of treatment the patient remained free of disease (LE 4 following Oxford CEBM Levels of Evidence).…”